131 related articles for article (PubMed ID: 15711732)
1. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?
Montuori N; Visconte V; Rossi G; Ragno P
Thromb Haemost; 2005 Feb; 93(2):192-8. PubMed ID: 15711732
[TBL] [Abstract][Full Text] [Related]
2. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
3. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
4. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
5. The cleavage of the urokinase receptor regulates its multiple functions.
Montuori N; Carriero MV; Salzano S; Rossi G; Ragno P
J Biol Chem; 2002 Dec; 277(49):46932-9. PubMed ID: 12297505
[TBL] [Abstract][Full Text] [Related]
6. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer.
Rasch MG; Lund IK; Almasi CE; Hoyer-Hansen G
Front Biosci; 2008 May; 13():6752-62. PubMed ID: 18508692
[TBL] [Abstract][Full Text] [Related]
7. Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR.
Montuori N; Ragno P
Front Biosci (Landmark Ed); 2009 Jan; 14(7):2494-503. PubMed ID: 19273214
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.
Sier CF; Nicoletti I; Santovito ML; Frandsen T; Aletti G; Ferrari A; Lissoni A; Giavazzi R; Blasi F; Sidenius N
Thromb Haemost; 2004 Feb; 91(2):403-11. PubMed ID: 14961171
[TBL] [Abstract][Full Text] [Related]
9. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
10. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo.
Sidenius N; Sier CF; Blasi F
FEBS Lett; 2000 Jun; 475(1):52-6. PubMed ID: 10854857
[TBL] [Abstract][Full Text] [Related]
11. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
12. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
[TBL] [Abstract][Full Text] [Related]
13. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
[TBL] [Abstract][Full Text] [Related]
14. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
[TBL] [Abstract][Full Text] [Related]
15. The urokinase receptor. A cell surface, regulated chemokine.
Blasi F
APMIS; 1999 Jan; 107(1):96-101. PubMed ID: 10190285
[TBL] [Abstract][Full Text] [Related]
16. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.
Carriero MV; Del Vecchio S; Capozzoli M; Franco P; Fontana L; Zannetti A; Botti G; D'Aiuto G; Salvatore M; Stoppelli MP
Cancer Res; 1999 Oct; 59(20):5307-14. PubMed ID: 10537314
[TBL] [Abstract][Full Text] [Related]
17. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Yebra M; Goretzki L; Pfeifer M; Mueller BM
Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.
van der Pluijm G; Sijmons B; Vloedgraven H; van der Bent C; Drijfhout JW; Verheijen J; Quax P; Karperien M; Papapoulos S; Löwik C
Am J Pathol; 2001 Sep; 159(3):971-82. PubMed ID: 11549590
[TBL] [Abstract][Full Text] [Related]
20. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling.
Madsen CD; Sidenius N
Eur J Cell Biol; 2008 Sep; 87(8-9):617-29. PubMed ID: 18353489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
